Белев Н., Атанасов Б., Русев П., Попов Щ., Кръстев П.
Belev N., Atanasov B., Rusev P., Popov Sht., Krustev P.
MBAL-Eurohospital, Plovdiv
Epithelial ovarian cancer ( EOC ) is the fifth most common type of cancer among women.
Ovarian carcinoma ( OC ) at an early stage has a high survival rate with surgery and chemotherapy ,
but 75% of patients had tumor exceeding the level of the pelvis (FIGO- stage III-IV) and long-term survival is low.
Advanced OC was treated with a combination of cytoreductive surgery ( MDG ) , and chemotherapy , which provides improved survival .
Purpose of surgery in these cases is to obtain a macroscopic tumor resection (complete cytoreduction ) of the disease.
National Cancer Institute of the United States ( NOI ) gives a recommendation in 2006 stating ,
hat intraperitoneal (IP) chemotherapy should be added to the treatment algorithm for patients with optimal cytoreduction .
Despite the advantage of this approach IP chemotherapy has not become routine because of : greater toxicity ,
lack of experience in the placement and management of indwelling catheter , the difficulty in the distribution of drugs throughout
peritoneal cavity due to adhesions and anatomic retsesusi . In recent years , the maximum cytoreductive
surgery combined with hyperthermic intraperitoneal chemotherapy ( HIHT ) has proven effective in the treatment of
colorectal carcinomatosis and was accepted as a standard for its treatment countries such as Germany , Italy, Spain and France .
The procedure takes advantage of the benefits of local therapy and the synergistic effect of hyperthermia and increased
concentration of cytostatic medikamenti.Naskoro results were published in the treatment of advanced epithelial cancer
ovary with the MDGs and HIHT showing significant advantage when adding HIHT . The purpose of this presentation is to analyze
Data currently available and presented the basic principles underlying HIHT